Application Note

Enabling High-Performing Perfusion Cell Culture


It is estimated that by 2025, 35% of biologics will be manufactured using process intensification methods, including perfusion-based bioprocessing. Advancement of the biopharma industry in this direction means there will be significantly higher demands placed upon both the equipment and consumables to drive these processes forward. This increased interest in performance creates an opportunity for improvement in consistent scalability as well as process design and management.

Follow along as we examine two innovations to increase process performance and clear a path toward production scale-up.

access the Application Note!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online